Lg Cwd
icon-nav-help
Need Help

Submit your question to our team of health care professionals.

icon-nav-current-questions
Current Question

See what's on the mind of the community right now.

icon-conf-speakers-at-a-glance
Meet the Team

Learn more about our world-renowned team.

icon-nav-archives
DTeam Archives

Review the entire archive according to the date it was posted.

icon-question-mark
July 17, 2000

Insulin

Question from Egg Harbor Township, New Jersey, USA:

I understand there is a new 24 hour long acting insulin which has just been approved for marketing by the FDA. It is Lantus Glargine, made by Hoechst. Will this be a better option than NPH or Ultralente for a 4 year old recently diagnosed Type 1 child? What are your thoughts on the new insulin, and when will it be available by prescription?

Answer:

Glargine is a new insulin analog that offers a very even release over the 24 hours after injection. Basically it is equivalent to two injections of NPH over the same period; but otherwise affords no striking improvement in control. It is likely to find a place in intensive insulin therapy where it is used with a Humalog dose after meals that is adjusted for the premeal blood sugar and appetite.

DOB

[Editor’s comment: Insulin glargine is marketed by Aventis Pharmaceuticals under the brand name Lantus.

JSH]